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PericyteRetinal pericyte loss and neovascularization are characteristic features of diabetic retinopathy. Gemigliptin, a
dipeptidyl peptidase-4 (DPP-4) inhibitor, has shown robust blood-glucose lowering effects in type 2 diabetic pa-
tients, but its effects on diabetic retinopathy have not yet been reported.We evaluated the efﬁcacy of gemigliptin
on retinal vascular leakage in db/dbmice,which is an animalmodel for type 2 diabetes, and neovascularization in
oxygen-induced retinopathy (OIR) mice, which is an animal model for ischemic proliferative retinopathy.
Gemigliptin (100mg/kg/day)was orally administered to the db/dbmice for 12weeks. C57BL/6mice on postnatal
day 7 (P7)were exposed to 75% hyperoxia for 5 days, followed by exposure to room air fromP12 to P17 to induce
OIR. Gemigliptin (50mg/kg/day)was intraperitoneally injected daily from P12 to P17. Retinal neovascularization
was analyzed inﬂat-mounted retinas on P17.Wedetermined the efﬁcacy and possiblemechanismof gemigliptin
on high glucose-induced apoptosis of primary human retinal pericytes. The oral administration of gemigliptin for
4months signiﬁcantly ameliorated retinal pericyte apoptosis and vascular leakage in the db/dbmice. Gemigliptin
also ameliorated retinal neovascularization in the OIR mice. Gemigliptin attenuated the overexpression of
plasminogen activator inhibitor-1 (PAI-1) in the retinas of diabetic and OIR mice. Gemigliptin and PAI-1 siRNA
signiﬁcantly inhibited pericyte apoptosis by inhibiting the overexpression of PAI-1, which is induced by high glu-
cose. Our results suggest that gemigliptin has potent anti-angiogenic and anti-apoptotic activities via suppressing
DPP-4 and PAI-1, and the results support the direct retinoprotective action of gemigliptin.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Diabetic retinopathy is a common and seriousmicrovascular compli-
cation of diabetes [1]. The normal function of retinal vessels requiresdipeptidyl peptidase-4; GLP-1,
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ollege of Veterinary Medicine,interactions between the inner endothelial cells and surrounding
pericytes [2]. Pericyte loss is one of the earliest detectable lesions in
the diabetic retina [3] and may be responsible for the retinal vascular
leakage and sight-threatening neovascularization [4]. Pericytes express
several angiogenic growth factors, which are critical for determining
whether vessels are stable or will undergo angiogenesis [5]. The current
management strategy for diabetic retinopathy is focused on early
detection and tight glycemic control to slow the progression of the
disease. However, the persistence of hyperglycemic stress despite
glucose normalization has been observed in the diabetic retina [6,
7]. Previous studies have shown that vascular endothelial cells and
retinal pigment epithelial cells previously exposed to high glucose
continued to display a reactive oxygen species (ROS)-mediated cellular
stress despite subsequent normalization of glucose concentration in the
media [7]. Indeed, althoughmany classes of glucose-lowering oral agents
have been available for clinical use, the prevalence of diabetic retinopathy
is increasing [8].
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anti-diabetic drugs that increase the levels of a gastrointestinal incretin
hormone, glucagon-like peptide-1 (GLP-1), by inhibiting its cleavage.
DPP-4 inhibitors show glucose-dependent activity by increasing insulin
secretion, inhibiting glucagon secretion, and increasing β-cell mass,
thereby producing lower blood glucose levels [9]. Recently, Blaslov
et al. reported that circulating DPP-4 activity is associated with the
progression and severity of diabetic retinopathy [10]. Several DPP-4
inhibitors were shown to have protective effects against diabetic reti-
nopathy. Sitagliptin inhibited retinal vascular leakage, inﬂammation
and neuronal apoptosis in both type 1 and type 2 diabetic rats [11,12].
Vildagliptin down-regulated the gene expression levels of angiogenic
growth factors, such as vascular endothelial growth factor (VEGF),
intercellular adhesion molecule-1 (ICAM-1), plasminogen activator
inhibitor-1 (PAI-1) and pigment epithelium-derived factor (PEDF) in
the retinas of obese type 2 diabetic rats [13]. Saxagliptin improved reti-
nal capillary ﬂow in diabetic patientswithout the clinical signs ofmicro-
vascular alteration [14]. However, the precise mechanisms of DPP-4
inhibitors against diabetic retinopathy beyond its glucose-lowering
role are still not well understood.
Gemigliptin is a highly selective DPP-4 inhibitor developed in Korea
and has been clinically used as an oral agent for type 2 diabetes [15]. Pre-
vious in vitro and in vivo data suggest that gemigliptin also exerts a num-
ber of additional activities, including anti-glycation, anti-inﬂammation
and renoprotective effects [16–19]. To the best of our knowledge, there
have been no reports on the effects of DPP-4 inhibitors on retinal pericyte
injury andneovascularization. Therefore,we studiedwhether gemigliptin
inhibits retinal pericyte injury through the modulation of apoptotic cas-
cades in type 2 diabetic db/db mice. Additionally, we evaluated whether
gemigliptin effectively prevents retinal neovascularization in oxygen-
induced retinopathy (OIR) mice.
2. Materials and methods
2.1. Animals
Six-week-old male C57BL/KsJ-Leprdb/db diabetic mice (db/db) and
nondiabetic heterozygous littermates (db/+) were purchased from
Japan SLC (Shizuoka, Japan). C57BL/6 mice were purchased from Orient
Bio (Seoul, Korea). The care and use of the animals were approved by
the Animal Welfare Review Board of LG Life Sciences (LGMD13-083;
approval date 01/07/2014).
2.2. Type 2 diabetic db/db mice
After 2 weeks of acclimatization, the db/+ and db/db mice were
divided into the following three groups: the db/+ group (n = 10), the
db/db group (n= 10) and the gemigliptin group (n= 10). Gemigliptin
(100 mg/kg body weight; LG Life Sciences, Seoul, Korea) or an equal
amount of vehicle (0.5% methylcellulose solution) was administered
to diabetic db/db mice by oral gavage daily for 12 weeks. Non-diabetic
littermates received the same amount of methylcellulose solution. The
blood glucose levels were recorded every week.
2.3. OIR mice and analysis of retinal neovascularization
OIR was induced in C57BL/6 mice. On postnatal day 12 (P12), after
the mice were exposed to 75 ± 2% oxygen for 5 days (P7–P12), they
were returned to room air and randomly assigned to two groups:
vehicle-treated OIR mice and gemigliptin-treated (50 mg/kg/day) OIR
mice. The normal control miceweremaintained under room conditions
frombirth until postnatal day 17 (P17). Gemigliptinwasdilutedwith 5%
dimethyl sulfoxide (Sigma, St. Louis, MO, USA) in saline. The mice were
injected intraperitoneally with 100 μL of this solution daily for 5 days.
The vehicle solution was injected in the normal control group. On
P17, the mice were anesthetized and sacriﬁced. Fluorescein retinalangiography and Bandeiraea simplicifolia isolectin B4 staining for
the quantiﬁcation of preretinal neovascular tufts were performed
according to a method described previously [20]. Brieﬂy, preretinal
neovascularization areas were outlined and quantiﬁed in each quad-
rant of the retina as a percentage of total area of retina analyzed.
2.4. Trypsin digest preparation to isolate retinal vascular beds
Each retina was carefully isolated under a microscope. After ﬁxation
in 4% paraformaldehyde for 24 h, the retinas were incubated in 3% tryp-
sin (Sigma, St. Louis, MO, USA) in sodium phosphate buffer containing
100mmol/LNaF for 1 h to inhibit theDNase activity. The retinal vascular
beds were separated from the retinal tissue by gentle rinsing in
phosphate-buffered saline (PBS) and transferred to microscope slides.
2.5. Determination of the endothelial cells/pericytes (E/P) ratio
The retinas (n=10) fromeach groupwere isolated, and the trypsin-
digested retinal vessels were stained with periodic acid Schiff base
reagent. Pericytes and endothelial cells were identiﬁed based on the
morphology and relative location to the capillaries. The E/P ratio was
calculated using a previously established method [21]. To determine
the E/P ratio, the total numbers of pericytes and endothelial cells were
counted in 10 randomly selected areas (magniﬁcation 400×) in the
middle one-third of the retinal capillary area. Samples were examined
by 3 ophthalmic pathologists in a blinded fashion.
2.6. TUNEL assay and immunoﬂuorescence staining
The retinal digests were incubated with a mouse anti-NG2 antibody
(Chemicon, Temecula, CA, USA), a mouse anti-PAI-1 antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), and a TUNEL ﬂuorescein kit
(Promega, Madison, WI, USA). Nuclei were counterstained with
diamidinophenylindole (DAPI, Sigma). For the quantiﬁcation of
pericyte density, 4 ﬁelds of view (mm2) were randomly collected
in the retinal digests from each mouse. The number of NG-2-positive
was counted, and the number of pericytes was standardized by the
number of DAPI-positive cells (number of NG2-positive cells per
100 DAPI-positive cells). TUNEL-positive cells were determined by
counting per mm2 of capillary area.
2.7. Retinal ﬂuorescein isothiocyanate–dextran leakage
Mice were deeply anesthetized with zolazepam (Virbac, Carros,
France). Then, a solution of 50 mg/kg of ﬂuorescein isothiocyanate
(FITC)–dextran (a molecular weight of 4.4 kDa, Sigma) in PBS (pH 7.4)
was injected into the left ventricle. After circulation for 10 min, the ret-
inas were isolated and transferred onto a microscope slide. Pictures
were taken using a ﬂuorescence microscope (Olympus, Tokyo, Japan).
To quantify retinal vascular permeability, the mice were perfused
with PBS (500 mL/kg body weight) for 6 min. Plasma was also col-
lected before perfusion. The retina of each eye was isolated, weighed
and homogenized in 200 μL of distilled water. The homogenate was
centrifuged at 15,000 rpm for 20 min, and the supernatant was
collected. The ﬂuorescence in each 100 μL sample was measured using a
spectroﬂuorophotometer (Bio-Tek, Winooski, VT, USA). The amount of
FITC–dextran leakage into the retinal tissues was calculated using the fol-
lowing equation: retinal FITC–dextran leakage = [retinal FITC–dextran
(μg) / retinal weight (g)] / [plasma FITC–dextran (μg/μL) × circulation
time (min)].
2.8. Immunoﬂuorescence staining for occludin in retinal whole mounts
The whole retinas from each group were ﬁxed with 4% paraformal-
dehyde for 24 h. The retinas were blocked and permeabilized in 10%
normal donkey serum with 0.3% Triton in PBS for 1 h. The retinas
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CA, USA) in block solution for 48 h at 4 °C. The retinas were washed for
30 min at room temperature and then incubated for 2 h at 4 °C with
rhodamine-conjugated donkey anti-mouse immunoglobulin G (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). All retinas were ﬂat mounted
and viewed with a ﬂuorescence microscope (Olympus, Tokyo, Japan).2.9. Protein array
On P17, the mice were anesthetized and sacriﬁced. Each retina was
carefully isolated under a microscope. The retinas were homogenized in
PBS using protease inhibitors and centrifuged at 10,000 ×g for 5 min,
and the total protein concentrations were quantiﬁed. To determine the
expression levels of angiogenesis-related factors, protein arrays were
performedusing a kit (ProteomeProﬁler™MouseAngiogenesis Antibody
Array Kit, R&D Systems, Abingdon, UK). Optical density measurements
were performed using ImageJ software (NIH, Bethesda, MD, USA). A list
of the 55 factors can be found on the manufacturer's webpage.2.10. DPP-4 enzymatic activity assay
Plasma DPP-4 enzymatic activity was assessed using a DPP-4 Activity
Assay Kit (Biovision, Milpitas, CA, USA) according to the manufacturer's
instructions. DPP-4 activity was calculated using the cleavage rate of
7-amino-4-methylcoumarin per min per mL.2.11. Primary human retinal pericyte culture
Primary human retinal pericytes (Cell Systems, Kirkland, WA,
USA) were maintained in the speciﬁed Pericyte Media (PromoCell,
Heidelberg, Germany). Pericytes were cultured at 37 °C in a humidiﬁed
atmosphere of 5% CO2 and 95% air. The cells were plated in 6-well plates
and were used in experiments when the cells were approximately 80%
conﬂuent.2.12. Apoptosis assay using ﬂow cytometry
Pericytes were treated with normal glucose (5 mmol/L) and high
glucose (30 mmol/L) in the presence or absence of gemigliptin at
various concentrations (0, 1, 10 and 100 mmol/L) for 1 week. Mannitol
(30 mmol/L) was used as an osmotic control. To determine the
effect of DPP-4 and PAI-1 suppression, pericytes were transfected with
40 nmol/L DPP-4 siRNA (Santa Cruz Biotechnology), PAI-1 siRNA (Santa
Cruz Biotechnology), or a corresponding scrambled siRNA using
Lipofectamine™ 2000 (Invitrogen, Frederick, MD, USA) 24 h before
treatment with high glucose. Pericytes were then collected and stained
with an Annexin V-FITC/propidium iodide (PI) Apoptosis Detection Kit
(Invitrogen) according to the manufacturer's instructions. Apoptosis
was examined using a ﬂow cytometer (Becton Dickinson, San Jose, CA,
USA). The cells that stained positively with annexin V but not with PI
were considered apoptotic cells.Fig. 1. Blood glucose levels. Values are expressed as the mean ± SEM, n = 10.2.13. Western blot analysis
Protein lysates were analyzed using sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis and transferred to polyvinylidene
diﬂuoride membranes (Bio-Rad, Hercules, CA, USA). The membranes
were labeled with mouse anti-DPP-4 (Santa Cruz Biotechnology)
and mouse anti-PAI-1 antibody (Santa Cruz Biotechnology). The immu-
noreactive bands were detected using chemiluminescence detection
reagents (Pierce, Rockford, IL, USA), and the density of the bands-of-
interest was further measured using a LAS-3000 machine (Fujiﬁlm,
Tokyo, Japan).2.14. Statistical analysis
Data are expressed as themean± standard error of themean (SEM).
Differences between groups were assessed using one-way ANOVA and
Tukey's multiple comparison test in the Prism 6.0 program (GraphPad,
La Jolla, CA, USA), and P b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Gemigliptin inhibits diabetes-induced retinal pericyte injury
The mice with a blood glucose concentration exceeding 300 mg/dL
were considered diabetic. In the normal db/+mice, blood glucose levels
were b150 mg/dL. The blood glucose levels in the db/db mice were
N300 mg/dL at 8 weeks of age and gradually increased over the treat-
ment period. Interestingly, gemigliptin treatment did not affect the
blood glucose levels throughout the treatment period (Fig. 1).
We used retinal digest preparations to determine the presence of
pericyte loss. The E/P ratio was calculated to determine pericyte density
in the retinal vasculature. The E/P ratiowas signiﬁcantly increased in the
db/dbmice compared to that of normal db/+mice, whereas the E/P ratio
for the gemigliptin-treatedmicewas signiﬁcantly reduced (Fig. 2A andB).
To conﬁrm pericyte loss, we performed immunoﬂuorescence analysis for
NG2, which is a pericytemarker. As shown in Fig. 2C, the number of NG2-
positive cells signiﬁcantly decreased in the vehicle-treated db/db mice
compared with normal db/+ mice. However, gemigliptin signiﬁcantly
inhibited the reduction of NG2-positive cells in db/db mice. We per-
formed TUNEL staining to further conﬁrm that the reduction in pericyte
density in db/db mice was due to apoptosis. The retinal vessels of the
db/db mice showed many TUNEL-positive pericytes and endothelial
cells, whereas normal db/+mice and gemigliptin-treated db/dbmice ex-
hibited few positive cells (Fig. 2D). These ﬁndings suggest that the loss of
retinal pericytes occurred indb/dbmice and that gemigliptinmight inhib-
it diabetes-induced pericyte apoptosis.
3.2. Gemigliptin decreases diabetes-induced BRB disruption
Weevaluated retinal vessel dysfunction using FITC–dextranmicrosco-
py. Oral gemigliptin treatment signiﬁcantly reduced retinal vascular leak-
age in db/db mice compared with the vehicle-treated db/db mice, to a
level that was similar to normal db/+mice (Fig. 3A and B). Next, the ret-
inal vessels were immunostained for occludin to examine gemigliptin ef-
fects on tight junction protein loss in the retinal microvasculature. Retinal
Fig. 2. Inhibitory effects of gemigliptin on diabetes-induced pericyte loss. (A) Periodic acid Schiff and hematoxylin-stained retinal digestedmicrovessels. Pericyteswere identiﬁed in retinal
digest preparations based onmorphologic criteria (shape, staining intensity, and relative position in the capillary) and quantiﬁed. The arrows indicate representative pericytes. (B) The E/P
ratio was calculated. (C) Immunoﬂuorescence staining for NG2 (green) in retinal vessels. Vessels were counterstained with DAPI (blue). The number of pericytes was determined by
counting the number of NG2 positive cells per mm2 of capillary area. (D) TUNEL staining. TUNEL-positive nuclei were counted per mm2 capillary area. Data are expressed as the
mean ± SEM, n = 10. *P b 0.05 vs. db/+ mice, #P b 0.05 vs. db/db mice.
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retinal vasculature in normal db/+mice, multiple alterations in the sub-
cellular distribution of occludin proteinswere observed in the retinal ves-
sels of vehicle-treated db/db mice, but gemigliptin signiﬁcantly restored
the decrease in occludin protein levels in db/db mice compared with
vehicle-treated db/db mice to levels that were comparable to the retinas
of normal db/+ mice (Fig. 3C and D).
3.3. Gemigliptin attenuates retinal neovascularization in OIR mice
The above results indicate that the effects of gemigliptin on retinal
vascular alterations can be achieved without a reduction of hyperglyce-
mia in db/db mice. To conﬁrmwhether gemigliptin's effects on diabetic
retinopathy occurred via the direct effects on the retina that independent-
ly affected blood glucose, nondiabetic OIR mice were used. Gemigliptin
was administered intraperitoneally once a day for 5 days from P12 in
OIR mice, which is a model of ischemia-induced retinopathy. Fluorescein
angiography at P17 indicated that the gemigliptin-treated retinas devel-
oped less retinal vascular leakage and neovascularization (Fig. 4A) com-
pared with vehicle-treated OIR retinas. The quantiﬁcation of preretinalneovascular tufts using isolectin B4 staining showed that the retinas treat-
ed with gemigliptin developed signiﬁcantly fewer preretinal neovascular
tufts, relative to the vehicle-treated OIR mice (Fig. 4B–D), supporting the
notion that gemigliptin has an anti-angiogenic effect. In addition, the ret-
inal vascular permeability assay showed that gemigliptin also signiﬁcant-
ly reduced retinal vascular leakage compared with vehicle-treated OIR
mice (Fig. 4E).
3.4. Gemigliptin regulates the expression of angiogenesis-related factors
We investigated the expression levels of 55 angiogenesis-related
factors in the retinas using a protein array to evaluate the direct effects
of gemigliptin on retinal neovascularization. As shown in Fig. 5,
gemigliptin decreased the expression of pro-angiogenic factors [stromal
cell-derived factor 1 (SDF-1), PAI-1,monocyte chemoattractant protein-
1 (MCP-1), placental growth factor-2 (PGF-2), and VEGF] in the OIR
mice compared with the vehicle-treated mice. Among these pro-
angiogenic factors, PAI-1 and MCP-1 displayed a N2-fold up-regulation
in the OIR group and a b2-fold down-regulation in the gemigliptin
group. The expression of insulin-like growth factor binding protein-1
Fig. 3. Inhibitory effects of gemigliptin on diabetes-induced blood–retinal barrier breakdown. (A) FITC–dextran angiography on retinal ﬂat mounts. (B) Quantitative analysis of retinal
vascular permeability. (C) Immunoﬂuorescence staining for occludin protein in retinal whole mounts. In normal db/+ mice, immunoreactivity for occludin was continuous at the cell
borders, whereas diabetes disrupted occludin immunoreactivity at the cell border and increased intracellular punctate labeling. Gemigliptin prevented the changes of occludin in db/db
mice. (D) Western blot analysis for occludin in retinal tissues. Values in the bar graphs represent the mean ± SEM, n = 10. *P b 0.05 vs. db/+mice, #P b 0.05 vs. db/db mice.
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cantly increased in the vehicle-treated OIR mice, but these pro-
angiogenic factors remained unaffected by gemigliptin treatment. Addi-
tionally, platelet factor-4 (PF-4), an anti-angiogenic factor, was also
down-regulated by gemigliptin compared to vehicle-treatment in the
OIR mice. The up-regulation of anti-angiogenic factors in vehicle-
treated OIR mice may have been due to a protective feedback mecha-
nism against angiogenesis. These results indicate that gemigliptinmight exert anti-angiogenic effects by inhibiting the expression of
SDF-1, PAI-1, MCP-1, PGF-2 and VEGF.
3.5. Gemigliptin inhibits high glucose-induced pericyte apoptosis in vitro
Pericytes were cultured in 30 mmol/L glucose for 1 week with vari-
ous concentrations of gemigliptin to determine whether gemigliptin
directly protects pericytes from apoptosis. The number of apoptotic
Fig. 4. Effect of gemigliptin on ischemia-induced retinal neovascularization. Mice were exposed to 75% oxygen from P7 to P12. The mice were returned to room air and received an intra-
peritoneal injection of 50mg/kg/day of gemigliptin for 5 days. (A) Retinal ﬂuorescein angiography at P17. The arrow indicates the area of retinal vascular leakage. (B) Isolectin B4-stained
retinal whole-mounts. (C) High-magniﬁcation images for isolectin B4-stained retinas (×100). The arrowhead indicates the area of neovascular tufts. (D) The preretinal neovascular area
wasmeasured and normalized to the total retinal area. (E) Quantitative analysis of retinal vascular permeability. Values in the bar graphs represent themean± SEM, n= 10. *P b 0.05 vs.
normal control mice, #P b 0.05 vs. OIR mice.
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gemigliptin inhibited pericyte apoptosis in a dose-dependent man-
ner (Fig. 6A). Pericyte apoptosis was further examined using TUNEL
staining. The TUNEL-positive pericytes were detectable under high
glucose conditions, whereas gemigliptin inhibited high-glucose-
induced pericyte apoptosis (Fig. 6B). These results support
our in vivo observation that gemigliptin inhibits pericyte injury in
db/db mice.3.6. High glucose-induced pericyte apoptosis is synergistically suppressed
by a combination treatment using gemigliptin and DPP-4 siRNA
To determine the effect of gemigliptin onDPP-4, plasmaDPP-4 activ-
ity and retinal DPP-4 protein levels were examined in db/db mice.
Gemigliptin decreased the activity of plasma DPP-4 to 40% of normal
db/+ mice, corresponding to a 50% decrease compared to db/db mice
(Fig. 7A). Retinal DPP-4 protein levels were also reduced by gemigliptin
Fig. 5. Effect of gemigliptin on the expression levels of 55 angiogenesis-relatedproteins. Thepositive controls are located in three corners of the arrays, and thenegative control is located in
the lower right corner of the arrays. Modulated proteins in retinas treated with gemigliptin are highlightedwith squares and indicated by numbers. The values in the bar graph represent
the mean ± SEM, n = 4. *P b 0.05 vs. normal control mice, #P b 0.05 vs. OIR mice.
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However, the retinal DPP-4 protein levels in db/dbmicemight be affected
by the extravasation of the soluble formof theprotein because retinal vas-
cular permeability was signiﬁcantly increased in the db/db mice and was
suppressed by gemigliptin. Moreover, the increased presence of extrava-
sated serum albumin into retinal parenchymawas also observed in db/db
mice (Fig. 7B).
We next examined DPP-4 protein levels in primary human retinal
pericytes under high glucose conditions with or without gemigliptin
treatment. DPP-4 is expressed at low levels under normal conditions.
However, high glucose induced pericyte apoptosis along withelevated DPP-4 protein levels (Fig. 7C and D). When pericytes
were treated with control siRNA or DPP-4 siRNAs, the DPP-4 siRNAs
markedly down-regulatedDPP-4 expression (Fig. 7C) and prevented high
glucose-induced pericyte apoptosis (a 59% reduction compared to the
high glucose group, Fig. 7D). Interestingly, a combination of DPP-4
siRNA with gemigliptin induced the enhanced apoptosis inhibition (an
87% reduction compared with the high glucose group) more than either
DPP-4 siRNA or gemigliptin alone (a 71% reduction), although treatment
with gemigliptin alone or a combination of siRNA and gemigliptin did not
reduce the expression of DPP-4 protein more than that of siRNA treat-
ment alone (Fig. 7C andD). These results suggest that the inhibitory effect
Fig. 6.Gemigliptin inhibits high glucose-inducedpericyte apoptosis. (A) Primary human retinal pericyteswere exposed to highglucose (HG, 30mmol/L) or normal glucose (NG, 5mmol/L)
for 1 week with or without gemigliptin (0, 1, 10 and 100 μmol/L). Apoptotic cells were detected using an FITC-labeled annexin V protein and ﬂow cytometry. (B) TUNEL staining at 100×
magniﬁcation. Each bar represents the mean ± SEM from three independent experiments. *P b 0.05 vs. normal glucose group, #P b 0.05 vs. high glucose group.
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caused not only by its ability to inactivate DPP-4 but also by its off-
target effects.
3.7. Gemigliptin suppressed PAI-1 expression, which inhibited high
glucose-induced pericyte apoptosis
A protein array indicated that gemigliptin markedly suppressed the
expression of PAI-1 andMCP-1. MCP-1 expression is increased in both di-
abetic and ischemic retinopathy. However, despite the pro-angiogenic
properties of MCP-1, MCP-1 deﬁciency did not prevent retinal neovascu-
larization in MCP−/− mice with ischemic retinopathy [22]. MCP-1 has
been shown to contribute to the recruitment of inﬂammatory cells into
thediabetic retina [23] and indirectly induces apoptosis in retinal pigment
epithelial cells by inﬁltrating inﬂammatory cells [24]. Based on these
ﬁndings, we can exclude the notion of MCP-1 directly promoting
retina neovascularization and diabetes-induced pericyte apoptosis.
Thus, we examined whether PAI-1 is involved in the inhibitory
role of gemigliptin in high glucose-induced pericyte apoptosis to
determine the underlying mechanisms by which gemigliptin
suppresses diabetic retinopathy. In db/db mice, PAI-1 protein was
increased 2.3-fold in retinal tissues compared with normal db/+
mice retinal tissues. Gemigliptin treatment signiﬁcantly decreased
retinal PAI-1 levels (Fig. 8A). Additionally, we examined the locali-
zation of PAI-1 in the retinal vasculature using immunostaining to
determine whether pericytes are the cellular source of PAI-1. As
expected, PAI-1 and NG-2 double-positive pericytes were observed
in db/db mice (Fig. 8B).
Based on the in vivo experiments, we also observed high glucose-
induced PAI-1 expression in primary human retinal pericytes (Fig. 8C).
When pericytes were transfected with control siRNA or PAI-1 siRNA,
the PAI-1 siRNA effectively down-regulated PAI-1 expression (Fig. 8C)
and also attenuated high glucose-induced pericyte apoptosis (Fig. 8D).
This PAI-1 overexpression and pericyte apoptosis induced by high glu-
cose was also signiﬁcantly inhibited by gemigliptin (Fig. 8C and D).
These data suggest that the effect of gemigliptin on high glucose-
induced pericyte apoptosis may be mediated at least in part through
the inhibition of PAI-1.4. Discussion
Few experimental studies have demonstrated the effect of DPP-4 in-
hibitors on diabetic retinopathy. One small clinical study in type 2
diabetic patients without retinopathy demonstrated that a DPP-4 inhib-
itor improved retinal capillary blood ﬂow and vasodilation [14]. Here,
we provide the ﬁrst evidence that gemigliptin has preventive effects
on diabetes-induced pericyte injury and ischemia-induced retinal
neovascularization. Furthermore, we demonstrated that the effects of
gemigliptin on retinal vascular alterations can be achieved without a
reduction of hyperglycemia in db/db mice or nondiabetic OIR mice,
suggesting that gemigliptin's protective effects are independent of its
effects on glucose homeostasis. More importantly, our results suggest
that the preventive effects of gemigliptin on diabetic retinopathy
occur through a PAI-1 dependent mechanism.
In the present study, gemigliptin did not reduce blood glucose levels
in db/db mice. Similarly, a previous report showed that alogliptin did
not exhibit beneﬁcial effects on blood glucose in db/db mice aged
between 8 and 16weeks. This ineffectiveness of DPP-4 inhibitors on hy-
perglycemia in this animal model can be explained by the reduction in
GLP-1 receptor expression in pancreas [25]. Therefore, we investigated
the retinoprotective possibility of gemigliptin in this animalmodel of di-
abetes independent of glucose levels.
DPP-4 inhibition has beneﬁcial effects on the vasculature [26], heart
[27] and brain [28]. Recently, Goncalves et al. reported that DPP-4 inhi-
bition also has beneﬁcial effects in retinal vessels and neurons [11]. DPP-
4 is widely expressed in various cells types [29] and in vascular endo-
thelial cells [30] and pericytes [31]. Regarding the retina, the expression
of DPP-4 protein was enhanced in the retinal tissues of STZ-induced di-
abetic rats, and immunoﬂuorescence staining showed that it wasmain-
ly expressed in ganglion cells [11]. Avolio et al. reported that DPP-4
mRNA was expressed at relatively low levels in pericytes under normal
conditions [31]. Consistentwith this report, our results showed that ret-
inal pericytes have relatively low expression levels of DPP-4 under nor-
mal conditions, but high glucose induces a signiﬁcant increase in DPP-4.
Gemigliptin prevented the increase in DPP-4 protein in pericytes with
high glucose. However, it has been claimed that the beneﬁcial effect of
DPP-4 inhibitors in the retina is mainly due to the inhibition of DPP-4.
Fig. 7.High glucose-induced pericyte apoptosis is synergistically suppressed by a combination treatment using gemigliptin and DPP-4 siRNA. (A) DPP-4 activity wasmeasured in the plas-
ma. (B) Retinal protein levels of DPP-4 were analyzed byWestern blotting. Values in the bar graphs represent the mean ± SEM, n= 4. *P b 0.05 vs. db/+mice, #P b 0.05 vs. db/db mice.
(C) After the pericyte transfection with control siRNA or DPP-4 siRNA, Western blot analysis for DPP-4 was performed in pericytes under high glucose (30 mmol/L) with or without
gemigliptin (100 μmol/L). (D) Apoptotic cell counts were assessed using FACS analysis. Data represent three independent experiments. Each bar represents the mean ± SEM from
three independent experiments. *P b 0.05 vs. normal glucose group, #P b 0.05 vs. high glucose group, †P b 0.05 vs. DPP-4 siRNA group.
2626 E. Jung et al. / Biochimica et Biophysica Acta 1852 (2015) 2618–2629Our study clearly showed that high glucose-induced pericyte
apoptosis was prevented by siRNA-mediated DPP-4 reduction. In
particular, a combination of DPP-4 siRNA with gemigliptin is more
effective than either DPP-4 siRNA or gemigliptin alone, although
gemigliptin alone or a combination of siRNA and gemigliptin did
not reduce the expression of DPP-4 proteins more than that of
siRNA treatment alone. Although we could not measure DPP-4 en-
zyme activity in the pericytes due to the technical limitations of
the assay sensitivity (data not shown), our results provide the initial
evidence that gemigliptin exerts a DPP-4 inhibitory action as well as
additional off-target activities in retinas.
The retina has the highest pericyte density among all vascular beds
[32]. Vasoregression in diabetic retinopathy starts with pericyte loss
[33]. Moreover, the loss of pericytes leads to increased vascular perme-
ability resulting in vascular leakage and macular edema [34]. A loss of
pericytes in diabetic retinopathy also triggers the development of acel-
lular capillaries and capillary nonperfusion,which leads to retinal ische-
mia and sight-threatening neovascularization [4]. Pericyte loss also
occurs in diabetic rodent models. Although it has been known that
pericytes begin to die relatively early in the course of diabetic retinopa-
thy, the time of onset of pericyte loss in db/db mice is a controversial
issue. Twenty three-week-old db/db mice have been shown to exhibitan increase in E/P ratio and acellular capillaries [21], and a more than
25% decrease in pericyte density was observed after 15 months of diabe-
tes in db/db mice [35]. TUNEL-positive apoptotic pericytes were found in
18-week-old db/db mice [36]. In this study, we terminated gemigliptin
treatment in db/db mice at 20 weeks of age. Similar to previous studies,
pericyte loss was already visible at this early time point.
Pericytes may be a valid target for the treatment of diabetic retinop-
athy. Here, we hypothesized that the reduction in PAI-1 by gemigliptin
may contribute to the inhibition of pericyte loss and retinal neovascu-
larization. To test the hypothesis, we examined the pathogenic role of
PAI-1 in human primary retinal pericytes under high glucose conditions
in the presence or absence of gemigliptin. The current study demon-
strates that both diabetic retinas in db/db mice and ischemic retinas in
OIRmice exhibited the PAI-1 overexpression. Gemigliptin treatment re-
stored its expression to near-normal levels in these animals, in parallel
with a marked inhibition in pericyte injury, vascular leakage and retinal
neovascularization. In addition, the down-regulation of PAI-1 with
siRNA ameliorated high glucose-induced pericyte apoptosis in vitro.
Consistent with these results, the reduction of PAI-1 by gemigliptin
treatment also attenuated pericyte injury under high glucose condi-
tions. These ﬁndings provide evidence that overexpressed PAI-1 in ret-
inal tissues confers its pro-apoptotic and angiogenic effects in the retina,
Fig. 8.Gemigliptin suppressed PAI-1 expression, which inhibited high glucose-induced pericyte apoptosis.(A) Retinal protein levels of PAI-1 were analyzed byWestern blotting. Values in
the bar graphs represent the mean ± SEM, n = 4. *Pb0.05 vs. db/+ mice, #Pb0.05 vs. db/db mice. (B) Immunoﬂuorescence staining for PAI-1 (red) and NG2 (green) in retinal vessels.
White arrows indicate PAI-1-expressed pericytes. (C) After the pericyte transfection with control siRNA or PAI-1 siRNA, Western blot analysis for PAI-1 was performed in pericytes
under high glucose (30 mmol/L) with or without gemigliptin (100 μmol/L). (D) Apoptotic cell counts were assessed by FACS analysis. Data represent three independent experiments.
Each bar represents the mean ± SEM from three independent experiments. *P b 0.05 vs. normal glucose group, #P b 0.05 vs. high glucose group.
2627E. Jung et al. / Biochimica et Biophysica Acta 1852 (2015) 2618–2629and gemigliptin inhibits the up-regulation of PAI-1, which may account
for its beneﬁcial effect in diabetic retinopathy and ischemia-induced
retinopathy.
PAI-1 is a primary regulator ofﬁbrinolysis and is a biosynthetic prod-
uct of retinal endothelial cells [37] and pericytes [38]. PAI-1 plays an im-
portant role in the development of diabetic retinopathy. High levels of
PAI-1 have been observed in serum [39], vitreous [40] and retinalmicro-
vasculature [41] of patients with diabetes. Furthermore, the retinal vas-
culature of transgenicmice that overexpress PAI-1 exhibited an increase
in the basal membranes and E/P ratio, similar to diabetic retinopathy
[42]. In an animal model of laser-induced choroidal neovascularization,
PAI-1 deﬁciency inhibited subretinal neovascularization in PAI-1−/−
mice, and the restoration of PAI-1 expression by an adenoviral vector
expressing human PAI-1 cDNA induced subretinal neovascularization
[43]. This ﬁnding is similar to the results of ischemia-induced retinal
neovascularization. The loss of PAI-1 reduced retinal neovascularization
in PAI-1−/−mice with OIR [44]. In contrast, the intravitreal injection of
exogenous human PAI-1 protein in rats with retinopathy of prematurity
inhibited retinal neovascularization [45]. This paradoxical role of PAI-1 inangiogenesis is dependent on the cell type and PAI-1 concentration [46].
High levels (micromolar) of PAI-1 prevented angiogenesis, whereas low
levels (physiological levels; nanomolar) of PAI-1 conversely facilitated
angiogenesis [47]. Taken together with results observed previously in
proliferative retinopathy models, our results conﬁrm that PAI-1 has pro-
angiogenic activity in retinal tissues under pathological conditions, such
as diabetes and hypoxia.
Additionally, apart from modulating angiogenesis, experimental
studies have shown that PAI-1 has both deleterious and beneﬁcial
effects on apoptosis. PAI-1 induces apoptosis in vascular endothelial
cells [48], whereas anti-apoptotic effects also have been observed in
these cells [49]. However, to date, there have been no reports on the
exact role of PAI-1 in retinal pericytes. We demonstrated that pericyte
loss occurred with PAI-1 increases in diabetic mice retinas, indicating
that pericyte loss may be partially correlated with PAI-1. Consistent
with a previous report [50], we also showed that high glucose induced
an up-regulation of PAI-1 in retinal pericytes. The down-regulation of
PAI-1 with siRNA suppressed high glucose-induced pericyte apoptosis.
These results suggest that PAI-1 down-regulation might be helpful for
2628 E. Jung et al. / Biochimica et Biophysica Acta 1852 (2015) 2618–2629the prevention of diabetic retinopathy. Although we did not provide
concrete evidence of whether PAI-1 deﬁciency actually ameliorates
diabetic retinopathy in animal models, the down-regulation of PAI-1
by gemigliptin reduced high-glucose-induced pericyte apoptosis both
in vitro and in vivo.
Gemigliptin has been used clinically to treat type 2 diabetes. Our sur-
prising ﬁnding of direct ocular effects of gemigliptin ondiabetic retinop-
athy and ischemia-induced retinopathy provides evidence that the oral
administration of gemigliptinmay be a promising therapeutic approach
to diabetic retinopathy. An oral dose of 50mg/day gemigliptin is recom-
mended for glycemic control in diabetic patients. Although we used a
relatively high dose of gemigliptin in animal models, a dose of 50 mg/
day gemigliptinmaybe sufﬁcient to obtain the same relative beneﬁcial ef-
fects on diabetic retinopathy in human subjects. The elimination half-life
of gemigliptin was shown to be 17.1 h [51]. The elimination half-life of
gemigliptin in db/db mice was 1.5 h (our unpublished data). Due to its
short half-life in db/db mice, we selected an oral dose of 100 mg/kg
gemigliptin for this animal model. Moreover, db/db mice are obese, and
their body surface area is approximately 2 times larger than that of nor-
mal C57BL/6 mice [52]. Thus, we also selected an oral dose of 50 mg/kg
gemigliptin for the OIR mice.
In summary, our study demonstrated that gemigliptin has both anti-
apoptotic and anti-angiogenic effects in the retinas of diabetic mice and
ischemia-induced retinopathy mice through the down-regulation of
PAI-1. These novel ﬁndings provide insight into the retinoprotective
effects of gemigliptin that are independent of glycemic control.
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